Login Register Cart 0
profile pic

Adolescent Psychiatry

Editor-in-Chief

ISSN (Print): 2210-6766
ISSN (Online): 2210-6774

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Effects of Cannabidiol in Adolescent and Young Adult Depressive and Anxiety Disorders: A Systematic Review of Clinical and Preclinical Research

Author(s): Rebecca K. Denson*, Julia Brooks, Graziano Pinna and Natania A. Crane

Volume 13, Issue 3, 2023

Published on: 04 October, 2023

Page: [176 - 194] Pages: 19

DOI: 10.2174/0122106766233339230919143924

Price: $65

Abstract

Background: Adolescents and young adults may use cannabidiol (CBD) products in an attempt to reduce depression and anxiety symptoms, despite little research examining this use. This systematic review evaluated preclinical and clinical research on the effects of CBD on depressive and anxiety disorders in adolescence and young adulthood. To provide context, we discuss CBD’s mechanism of action and neurodevelopmental effects.

Methods: PubMed was searched for articles published through June 2022. Preclinical or clinical CBD administration studies with N > 1 that examined depressive and/or anxiety disorders were eligible.

Results: Initially, 224 publications were identified. After excluding duplicates and applying eligibility criteria, 6 preclinical (depression: n≈133; anxiety: n≈161) and 4 clinical (anxiety: n=113) articles remained. Due to the low number of studies, results were synthesized qualitatively. The Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence were used to rate each study’s evidence. The preclinical effects of CBD on depression-like behavior appear to differ by sex, early life stress, and duration of use. Despite no evidence that CBD exerts anxiolytic effects in preclinical adolescent models, CBD may reduce anxiety symptoms in human adolescents and young adults with anxiety disorders.

Conclusion: The existing evidence suggests that CBD may reduce symptoms of anxiety in adolescents and young adults. However, the evidence is sparse and limited by variations in samples and CBD dosing duration. Further research is needed to understand the potential benefits and/or harms of CBD for depression and anxiety disorders in this population. Implications for clinical practice and research are discussed.

« Previous Next »
[]
Warning letters and test results for cannabidiol-related products., Available from: https://www-fda-gov.proxy.cc.uic.edu/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products
[]
Substance Abuse and Mental Health Services Administration. (2019) Substance Misuse Prevention for Young Adults. Publication No. PEP19-PL-Guide-1,
[]
Rockville, M.D.; Albaugh, M.D.; Ottino-Gonzalez, J.; Sidwell, A.; Lepage, C.; Juliano, A.; Owens, M.M.; Chaarani, B.; Spechler, P.; Fontaine, N.; Rioux, P.; Lewis, L.; Jeon, S.; Evans, A.; D’Souza, D.; Radhakrishnan, R.; Banaschewski, T.; Bokde, A.L.W.; Quinlan, E.B.; Conrod, P.; Desrivières, S.; Flor, H.; Grigis, A.; Gowland, P.; Heinz, A.; Ittermann, B.; Martinot, J.L.; Paillère, M.M.L.; Nees, F.; Papadopoulos, O.D.; Paus, T.; Poustka, L.; Millenet, S.; Fröhner, J.H.; Smolka, M.N.; Walter, H.; Whelan, R.; Schumann, G.; Potter, A.; Garavan, H. (2021), Association of cannabis use during adolescence with neurodevelopment. JAMA Psychiatry, 78(9), 1031.
[http://dx.doi.org/10.1001/jamapsychiatry.2021.1258] [PMID: 34132750]
[]
Anderson, L.L.; Doohan, P.T.; Oldfield, L.; Kevin, R.C.; Arnold, J.C.; Berger, M.; Amminger, G.P.; McGregor, I.S. (2021), Citalopram and cannabidiol.. J. Clin. Psychopharmacol., 41(5), 525-533.
[http://dx.doi.org/10.1097/JCP.0000000000001427] [PMID: 34121064]
[]
American Psychological Association. (2022). Depression Treatments for Children and Adolescents https://www.apa.org/depression-guideline/childrenand-adolescents.
[]
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed. text rev.)
[http://dx.doi.org/10.1176/appi.books.9780890425787]
[]
Bergamaschi, M.M.; Queiroz, R.H.C.; Chagas, M.H.N.; de Oliveira, D.C.G.; De Martinis, B.S.; Kapczinski, F.; Quevedo, J.; Roesler, R.; Schröder, N.; Nardi, A.E.; Martín-Santos, R.; Hallak, J.E.C.; Zuardi, A.W.; Crippa, J.A.S. (2011), Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219-1226.
[http://dx.doi.org/10.1038/npp.2011.6] [PMID: 21307846]
[]
Berger, M.; Li, E.; Rice, S.; Davey, C.G.; Ratheesh, A.; Adams, S.; Jackson, H.; Hetrick, S.; Parker, A.; Spelman, T.; Kevin, R.; McGregor, I.S.; McGorry, P.; Amminger, G.P. (2022), Cannabidiol for treatment-resistant anxiety disorders in young people. J. Clin. Psychiatry, 83(5), 21m14130.
[http://dx.doi.org/10.4088/JCP.21m14130] [PMID: 35921510]
[]
Berghuis, P.; Rajnicek, A.M.; Morozov, Y.M.; Ross, R.A.; Mulder, J.; Urbán, G.M.; Monory, K.; Marsicano, G.; Matteoli, M.; Canty, A.; Irving, A.J.; Katona, I.; Yanagawa, Y.; Rakic, P.; Lutz, B.; Mackie, K.; Harkany, T. (2007), Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science, 316(5828), 1212-1216.
[http://dx.doi.org/10.1126/science.1137406] [PMID: 17525344]
[]
Bis-Humbert, C.; García-Cabrerizo, R.; García-Fuster, M.J. (2020), Decreased sensitivity in adolescent versus adult rats to the antidepressant-like effects of cannabidiol. Psychopharmacology, 237(6), 1621-1631.
[http://dx.doi.org/10.1007/s00213-020-05481-4] [PMID: 32086540]
[]
Bis-Humbert, C.; García-Cabrerizo, R.; García-Fuster, M.J. (2021), Antidepressant-like effects of cannabidiol in a rat model of early-life stress with or without adolescent cocaine exposure. Pharmacol. Rep., 73(4), 1195-1202.
[http://dx.doi.org/10.1007/s43440-021-00285-5] [PMID: 34076862]
[]
Black, N.; Stockings, E.; Campbell, G.; Tran, L.T.; Zagic, D.; Hall, W.D.; Farrell, M.; Degenhardt, L. (2019), Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis. Lancet Psychiatry, 6(12), 995-1010.
[http://dx.doi.org/10.1016/S2215-0366(19)30401-8] [PMID: 31672337]
[]
Bonn-Miller, M.O.; Loflin, M.J.E.; Thomas, B.F.; Marcu, J.P.; Hyke, T.; Vandrey, R. (2017), Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708-1709.
[http://dx.doi.org/10.1001/jama.2017.11909] [PMID: 29114823]
[]
Botsford, S.L.; Yang, S.; George, T.P. (2020), Cannabis and cannabinoids in mood and anxiety disorders: Impact on illness onset and course, and assessment of therapeutic potential. Am. J. Addict., 29(1), 9-26.
[http://dx.doi.org/10.1111/ajad.12963] [PMID: 31577377]
[]
Corroon, J.; Phillips, J.A. (2018), A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res., 3(1), 152-161.
[http://dx.doi.org/10.1089/can.2018.0006] [PMID: 30014038]
[]
Crippa, J.A.S.; Derenusson, G.N.; Ferrari, T.B.; Wichert-Ana, L.; Duran, F.L.S.; Martin-Santos, R.; Simões, M.V.; Bhattacharyya, S.; Fusar-Poli, P.; Atakan, Z.; Filho, A.S.; Freitas-Ferrari, M.C.; McGuire, P.K.; Zuardi, A.W.; Busatto, G.F.; Hallak, J.E.C. (2011), Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J. Psychopharmacol., 25(1), 121-130.
[http://dx.doi.org/10.1177/0269881110379283] [PMID: 20829306]
[]
Dhopeshwarkar, A.; Mackie, K. (2014), CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? Mol. Pharmacol., 86(4), 430-437.
[http://dx.doi.org/10.1124/mol.114.094649] [PMID: 25106425]
[]
Dobson, E.T.; Bloch, M.H.; Strawn, J.R. (2019), Efficacy and tolerability of pharmacotherapy for pediatric anxiety disorders. J. Clin. Psychiatry, 80(1), 17r12064.
[http://dx.doi.org/10.4088/JCP.17r12064] [PMID: 30753760]
[]
Dow-Edwards, D.; Silva, L. (2017), Endocannabinoids in brain plasticity: Cortical maturation, HPA axis function and behavior. Brain Res, 1654(Pt B), 157 -164.
[http://dx.doi.org/10.1016/j.brainres.2016.08.037]
[]
Dubrow, G.A.; Pawar, R.S.; Srigley, C.; Fong Sam, J.; Talavera, C.; Parker, C.H.; Noonan, G.O. (2021), A survey of cannabinoids and toxic elements in hemp-derived products from the United States marketplace. J. Food Compos. Anal., 97, 103800.
[http://dx.doi.org/10.1016/j.jfca.2020.103800] [PMID: 35547641]
[]
Esposito, G.; Scuderi, C.; Valenza, M.; Togna, G.I.; Latina, V.; De Filippis, D.; Cipriano, M.; Carratù, M.R.; Iuvone, T.; Steardo, L. (2011), Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One, 6(12), e28668.
[http://dx.doi.org/10.1371/journal.pone.0028668] [PMID: 22163051]
[]
Fedorova, E.V.; Wong, C.F.; Ataiants, J.; Iverson, E.; Conn, B.M.; Lankenau, S.E. (2021), Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles. Drug Alcohol Depend., 221, 108648.
[http://dx.doi.org/10.1016/j.drugalcdep.2021.108648] [PMID: 33676073]
[]
Florensa-Zanuy, E.; Garro-Martínez, E.; Adell, A.; Castro, E.; Díaz, Á.; Pazos, Á.; Mac-Dowell, K.S.; Martín-Hernández, D.; Pilar-Cuéllar, F. (2021), Cannabidiol antidepressant-like effect in the lipopolysaccharide model in mice: Modulation of inflammatory pathways. Biochem. Pharmacol., 185, 114433.
[http://dx.doi.org/10.1016/j.bcp.2021.114433] [PMID: 33513342]
[]
FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Available from: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
[]
Goodman, S.; Wadsworth, E.; Schauer, G.; Hammond, D. (2022), Use and perceptions of cannabidiol products in canada and in the United States. Cannabis Cannabinoid Res., 7(3), 355-364.
[http://dx.doi.org/10.1089/can.2020.0093] [PMID: 33998872]
[]
Goodwin, R.D.; Weinberger, A.H.; Kim, J.H.; Wu, M.; Galea, S. (2020), Trends in anxiety among adults in the United States, 2008–2018: Rapid increases among young adults. J. Psychiatr. Res., 130, 441-446.
[http://dx.doi.org/10.1016/j.jpsychires.2020.08.014] [PMID: 32905958]
[]
The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine.. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
[]
Hammond, D.; Goodman, S.; Wadsworth, E.; Rynard, V.; Boudreau, C.; Hall, W. (2020), Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. Int. J. Drug Policy, 77, 102698.
[http://dx.doi.org/10.1016/j.drugpo.2020.102698] [PMID: 32113149]
[]
Hegazy, O.; Platnick, H. (2019), Cannabidiol (CBD) for treatment of neurofibromatosis-related pain and concomitant mood disorder: A case report. Cureus, 11(12), e6312.
[http://dx.doi.org/10.7759/cureus.6312] [PMID: 31938604]
[]
Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. (2002), International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54(2), 161-202.
[http://dx.doi.org/10.1124/pr.54.2.161] [PMID: 12037135]
[]
Izzo, A.A.; Sharkey, K.A. (2010), Cannabinoids and the gut: New developments and emerging concepts. Pharmacol. Ther., 126(1), 21-38.
[http://dx.doi.org/10.1016/j.pharmthera.2009.12.005] [PMID: 20117132]
[]
Jurkus, R.; Day, H.L.L.; Guimarães, F.S.; Lee, J.L.C.; Bertoglio, L.J.; Stevenson, C.W. (2016), Cannabidiol regulation of learned fear: Implications for treating anxiety-related disorders. Front. Pharmacol., 7, 454.
[http://dx.doi.org/10.3389/fphar.2016.00454] [PMID: 27932983]
[]
Kaplan, J.S.; Wagner, J.K.; Reid, K.; McGuinness, F.; Arvila, S.; Brooks, M.; Stevenson, H.; Jones, J.; Risch, B.; McGillis, T.; Budinich, R.; Gambell, E.; Predovich, B. (2021), Cannabidiol exposure during the mouse adolescent period is without harmful behavioral effects on locomotor activity, anxiety, and spatial memory. Front. Behav. Neurosci., 15, 711639.
[http://dx.doi.org/10.3389/fnbeh.2021.711639] [PMID: 34512286]
[]
Kasten, C.R.; Zhang, Y.; Boehm, S.L., II (2019), Acute cannabinoids produce robust anxiety-like and locomotor effects in mice, but long-term consequences are age- and sex-dependent. Front. Behav. Neurosci., 13, 32.
[http://dx.doi.org/10.3389/fnbeh.2019.00032] [PMID: 30842732]
[]
Kedzior, K.K.; Laeber, L.T. (2014), A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- a meta-analysis of 31 studies. BMC Psychiatry, 14(1), 136.
[http://dx.doi.org/10.1186/1471-244X-14-136] [PMID: 24884989]
[]
Kessler, R.C.; Petukhova, M.; Sampson, N.A.; Zaslavsky, A.M.; Wittchen, H.U. (2012), Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int. J. Methods Psychiatr. Res., 21(3), 169-184.
[http://dx.doi.org/10.1002/mpr.1359] [PMID: 22865617]
[]
Khan, R.; Naveed, S.; Mian, N.; Fida, A.; Raafey, M.A.; Aedma, K.K. (2020), The therapeutic role of Cannabidiol in mental health: A systematic review. J. Cannabis Res., 2(1), 2.
[http://dx.doi.org/10.1186/s42238-019-0012-y] [PMID: 33526132]
[]
Klier, C.M.; de Gier, C.; Felnhofer, A.; Laczkovics, C.; Amminger, P.G. (2020), A case report of cannabidiol treatment of a crohn’s disease patient with anxiety disorder. J. Clin. Psychopharmacol., 40(1), 90-92.
[http://dx.doi.org/10.1097/JCP.0000000000001152] [PMID: 31834086]
[]
Laczkovics, C.; Kothgassner, O.D.; Felnhofer, A.; Klier, C.M. (2021), Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Neuropsychiatrie, 35(1), 31-34.
[http://dx.doi.org/10.1007/s40211-020-00334-0] [PMID: 32052321]
[]
Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.M.; Denovan-Wright, E.M. (2015), Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. Br. J. Pharmacol., 172(20), 4790-4805.
[http://dx.doi.org/10.1111/bph.13250] [PMID: 26218440]
[]
Ledesma-Corvi, S.; Hernández-Hernández, E.; García-Fuster, M.J. (2022), Exploring pharmacological options for adolescent depression: a preclinical evaluation with a sex perspective. Transl. Psychiatry, 12(1), 220.
[http://dx.doi.org/10.1038/s41398-022-01994-y] [PMID: 35650182]
[]
Locci, A.; Pinna, G. (2019), Stimulation of peroxisome proliferator-activated receptor-α by n-palmitoylethanolamine engages allopregnanolone biosynthesis to modulate emotional behavior. Biol. Psychiatry, 85(12), 1036-1045.
[http://dx.doi.org/10.1016/j.biopsych.2019.02.006] [PMID: 30955840]
[]
Locher, C.; Koechlin, H.; Zion, S.R.; Werner, C.; Pine, D.S.; Kirsch, I.; Kessler, R.C.; Kossowsky, J. (2017), Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents. JAMA Psychiatry, 74(10), 1011-1020.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.2432] [PMID: 28854296]
[]
Mackie, K. (2005), Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol., 168(168), 299-325.
[http://dx.doi.org/10.1007/3-540-26573-2_10] [PMID: 16596779]
[]
Mansell, H.; Quinn, D.; Kelly, L.E.; Alcorn, J. (2022), Cannabis for the treatment of attention deficit hyperactivity disorder: A report of 3 cases. Med. Cannabis Cannabinoids, 5(1), 1-6.
[http://dx.doi.org/10.1159/000521370] [PMID: 35224434]
[]
Masataka, N. (2019), Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front. Psychol., 10, 2466.
[http://dx.doi.org/10.3389/fpsyg.2019.02466] [PMID: 31787910]
[]
Matrisciano, F.; Pinna, G. (2021), PPAR-α hypermethylation in the hippocampus of mice exposed to social isolation stress is associated with enhanced neuroinflammation and aggressive behavior. Int. J. Mol. Sci., 22(19), 10678.
[http://dx.doi.org/10.3390/ijms221910678] [PMID: 34639019]
[]
Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. (1990), Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284), 561-564.
[http://dx.doi.org/10.1038/346561a0] [PMID: 2165569]
[]
McPartland, J.M.; Glass, M.; Pertwee, R.G. (2007), Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol., 152(5), 583-593.
[http://dx.doi.org/10.1038/sj.bjp.0707399] [PMID: 17641667]
[]
Mead, A. (2017), The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav., 70(Pt B), 288-291.
[http://dx.doi.org/10.1016/j.yebeh.2016.11.021]
[]
Medina, K.L.; Nagel, B.J.; Park, A.; McQueeny, T.; Tapert, S.F. (2007), Depressive symptoms in adolescents: Associations with white matter volume and marijuana use. J. Child Psychol. Psychiatry, 48(6), 592-600.
[http://dx.doi.org/10.1111/j.1469-7610.2007.01728.x] [PMID: 17537075]
[]
Meissner, H.; Cascella, M. , (2022). Cannabidiol (CBD). StatPearls;
[]
Melas, P.A.; Scherma, M.; Fratta, W.; Cifani, C.; Fadda, P. (2021), Cannabidiol as a potential treatment for anxiety and mood disorders: Molecular targets and epigenetic insights from preclinical research. Int. J. Mol. Sci., 22(4), 1863.
[http://dx.doi.org/10.3390/ijms22041863] [PMID: 33668469]
[]
Meyer, H.C.; Lee, F.S.; Gee, D.G. (2018), The role of the endocannabinoid system and genetic variation in adolescent brain development. Neuropsychopharmacology, 43(1), 21-33.
[http://dx.doi.org/10.1038/npp.2017.143] [PMID: 28685756]
[]
Millar, S.A.; Stone, N.L.; Yates, A.S.; O’Sullivan, S.E. (2018), A systematic review on the pharmacokinetics of cannabidiol in humans. Front. Pharmacol., 9, 1365.
[http://dx.doi.org/10.3389/fphar.2018.01365] [PMID: 30534073]
[]
Miller, M.L.; Chadwick, B.; Dickstein, D.L.; Purushothaman, I.; Egervari, G.; Rahman, T.; Tessereau, C.; Hof, P.R.; Roussos, P.; Shen, L.; Baxter, M.G.; Hurd, Y.L. (2019), Adolescent exposure to Δ9-tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture of prefrontal pyramidal neurons. Mol. Psychiatry, 24(4), 588-600.
[http://dx.doi.org/10.1038/s41380-018-0243-x] [PMID: 30283037]
[]
Miller, O.S.; Elder, E.J., Jr; Jones, K.J.; Gidal, B.E. (2022), Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Epilepsy Behav., 127, 108514.
[http://dx.doi.org/10.1016/j.yebeh.2021.108514] [PMID: 34998268]
[]
Munro, S.; Thomas, K.L.; Abu-Shaar, M. (1993), Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441), 61-65.
[http://dx.doi.org/10.1038/365061a0] [PMID: 7689702]
[]
Murphy, M.; Mills, S.; Winstone, J.; Leishman, E.; Wager-Miller, J.; Bradshaw, H.; Mackie, K. (2017), Chronic adolescent Δ9-tetrahydrocannabinol treatment of male mice leads to long-term cognitive and behavioral dysfunction, which are prevented by concurrent cannabidiol treatment. Cannabis Cannabinoid Res., 2(1), 235-246.
[http://dx.doi.org/10.1089/can.2017.0034] [PMID: 29098186]
[]
National Academies of Sciences. , (2017). The Health Effects of Cannabis and Cannabinoids. Washington (DC). National Academies Press US;
[]
O’Sullivan, S.E. (2016), An update on PPAR activation by cannabinoids. Br. J. Pharmacol., 173(12), 1899-1910.
[http://dx.doi.org/10.1111/bph.13497] [PMID: 27077495]
[]
Oberbarnscheidt, T.; Miller, N.S. (2020), The impact of cannabidiol on psychiatric and medical conditions. J. Clin. Med. Res., 12(7), 393-403.
[http://dx.doi.org/10.14740/jocmr4159] [PMID: 32655732]
[]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. (2021), The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[]
Piomelli, D.; Russo, E.B. (2016), The Cannabis sativa versus Cannabis indica Debate: An interview with Ethan Russo, MD. Cannabis Cannabinoid Res., 1(1), 44-46.
[http://dx.doi.org/10.1089/can.2015.29003.ebr] [PMID: 28861479]
[]
Ponton, J.A.; Smyth, K.; Soumbasis, E.; Llanos, S.A.; Lewis, M.; Meerholz, W.A.; Tanguay, R.L. (2020), A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: A case report. J. Med. Case Reports, 14(1), 162.
[http://dx.doi.org/10.1186/s13256-020-02478-7] [PMID: 32958062]
[]
Rubino, T.; Parolaro, D. (2016), The impact of exposure to cannabinoids in adolescence: Insights from animal models. Biol. Psychiatry, 79(7), 578-585.
[http://dx.doi.org/10.1016/j.biopsych.2015.07.024] [PMID: 26344755]
[]
Sarris, J.; Sinclair, J.; Karamacoska, D.; Davidson, M.; Firth, J. (2020), Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review. BMC Psychiatry, 20(1), 24.
[http://dx.doi.org/10.1186/s12888-019-2409-8] [PMID: 31948424]
[]
Schoeler, T.; Theobald, D.; Pingault, J.B.; Farrington, D.P.; Coid, J.W.; Bhattacharyya, S. (2018), Developmental sensitivity to cannabis use patterns and risk for major depressive disorder in mid-life: Findings from 40 years of follow-up. Psychol. Med., 48(13), 2169-2176.
[http://dx.doi.org/10.1017/S0033291717003658] [PMID: 29607801]
[]
Scuderi, C.; Steardo, L.; Esposito, G. (2014), Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytother. Res., 28(7), 1007-1013.
[http://dx.doi.org/10.1002/ptr.5095] [PMID: 24288245]
[]
Dickstein, D.; Dickstein, D.P. (2011), Anxiety in adolescents: Update on its diagnosis and treatment for primary care providers. Adolesc. Health Med. Ther., 3, 1-16.
[http://dx.doi.org/10.2147/AHMT.S7597] [PMID: 24600282]
[]
Silote, G.P.; Sartim, A.; Sales, A.; Eskelund, A.; Guimarães, F.S.; Wegener, G.; Joca, S. (2019), Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. J. Chem. Neuroanat., 98, 104-116.
[http://dx.doi.org/10.1016/j.jchemneu.2019.04.006] [PMID: 31039391]
[]
Simone, J.J.; Green, M.R.; McCormick, C.M. (2022), Endocannabinoid system contributions to sex-specific adolescent neurodevelopment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 113, 110438.
[http://dx.doi.org/10.1016/j.pnpbp.2021.110438] [PMID: 34534603]
[]
Stanciu, C.N.; Brunette, M.F.; Teja, N.; Budney, A.J. (2021), Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: A systematic review. Psychiatr. Serv., 72(4), 429-436.
[http://dx.doi.org/10.1176/appi.ps.202000189] [PMID: 33530732]
[]
The TEDS Report: Age of Substance Use Initiation among Treatment Admissions Aged 18 to 30. Substance Abuse and Mental Health Services Administration.
[]
Thomas, A.; Baillie, G.L.; Phillips, A.M.; Razdan, R.K.; Ross, R.A.; Pertwee, R.G. (2007), Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro. Br. J. Pharmacol., 150(5), 613-623.
[http://dx.doi.org/10.1038/sj.bjp.0707133] [PMID: 17245363]
[]
Tsuchida, A.; Laurent, A.; Crivello, F.; Petit, L.; Pepe, A.; Beguedou, N.; Debette, S.; Tzourio, C.; Mazoyer, B. (2021), Age-related variations in regional white matter volumetry and microstructure during the post-adolescence period: A cross-sectional study of a cohort of 1,713 university students. Front. Syst. Neurosci., 15, 692152.
[http://dx.doi.org/10.3389/fnsys.2021.692152] [PMID: 34413727]
[]
Substance Abuse and Mental Health Data Archive. Available from: https://datafiles.samhsa.gov/
[]
Vaughn, S.; Strawn, J.; Poweleit, E.; Sarangdhar, M.; Ramsey, L. (2021), The impact of marijuana on antidepressant treatment in adolescents: Clinical and pharmacologic considerations. J. Pers. Med., 11(7), 615.
[http://dx.doi.org/10.3390/jpm11070615] [PMID: 34209709]
[]
Viveros, M.P.; Llorente, R.; Suarez, J.; Llorente-Berzal, A.; López-Gallardo, M.; Rodriguez de Fonseca, F. (2012), The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J. Psychopharmacol., 26(1), 164-176.
[http://dx.doi.org/10.1177/0269881111408956] [PMID: 21669929]
[]
Wheeler, M.; Merten, J.W.; Gordon, B.T.; Hamadi, H. (2020), CBD (Cannabidiol) product attitudes, knowledge, and use among young adults. Subst. Use Misuse, 55(7), 1138-1145.
[http://dx.doi.org/10.1080/10826084.2020.1729201] [PMID: 32093530]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy